Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

Table 2 Disease progression and relapses for the intention-to-treat population for whom relapse/EDSS data were available (n=436)

Parameter	Number (%) patients
Parameter	Aged 41–50 years (n=301)	Aged >50 years (n=135)
EDSS score:
improvement (≤–1)	33 (11.0%)	12 (8.9%)
stable (no change)	219 (72.8%)	90 (66.7%)
progression (≥+1)	49 (16.3%)	33 (24.4%)
Relapse free throughout the study	272 (90.4%)	127 (94.1%)
Disease-progression free^a	252 (83.7%)	102 (75.6%)
Relapse free and disease-progression free	228 (75.7%)	96 (71.1%)

^aDisease-progression free defined as EDSS that were stable (change of up to ±1) or improved (at least 1-point decrease) at last patient visit.
EDSS expanded disability status scores.

ISSN: 1471-2377